Safety and Efficacy of Atorvastatin-Induced Very Low-Density Lipoprotein Cholesterol Levels in Patients With Coronary Heart Disease (a Post Hoc Analysis of the Treating to New Targets [TNT] Study)††Conflicts of interest: Dr. LaRosa has served as a consultant to Pfizer, Inc., New York, New York; Merck Whitehouse Station, New Jersey; Bristol-Myers Squibb, New York, New York; and AstraZeneca, Wilmington, Delaware; and has received lecture fees from Pfizer. Dr. Grundy has consulted with Abbott, Chicago, Illinois; GlaxoSmithKline, Durham, North Carolina, Pfizer, AstraZeneca, and Sanofi-Aventis, Bridgewater, New Jersey; received lecture fees from Merck Schering Plough, Kenilworth, New Jersey; Kos, Edison, New Jersey, Pfizer, GlaxoSmithKline, Lilly, and Bristol-Myers Squibb; and received research support from Abbott and GlaxoSmithKline. Dr. Kastelein has received consulting fees, lecture fees, and grant support from Pfizer, Merck Schering Plough, Bristol-Myers Squibb, and Sankyo, Munich, Germany; Dr. Kostis has served as a consultant to Pfizer, Schering Plough, Berlex, Montville, New Jersey; Taisho, Tokyo, Japan; Forest Laboratories, New York, New York; and Sankyo; received lecture fees from Pfizer, Merck, Bristol-Myers Squibb, AstraZeneca, Sanofi Aventis, and Otsuka, Rockville, Maryland; and received grant support from Pfizer and Schering Plough. Dr. Greten has received consulting and lecturing fees from Pfizer, Merck, Schering Plough, and Kowa Company, Nagoya, Japan.

2007 ◽  
Vol 100 (5) ◽  
pp. 747-752 ◽  
Author(s):  
John C. LaRosa ◽  
Scott M. Grundy ◽  
John J.P. Kastelein ◽  
John B. Kostis ◽  
Heiner Greten
Keyword(s):  
New York ◽  
North Carolina ◽  
New Jersey ◽  
Conflicts Of Interest ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Research Support ◽  
Cholesterol Levels ◽  
Grant Support ◽  
Post Hoc

Effects of the Cyclooxygenase Inhibiting Nitric Oxide Donator Naproxcinod Versus Naproxen on Systemic Blood Pressure in Patients With Osteoarthritis††Conflicts of interest: Dr. White reports receiving research support during the past 12 months from the National Institutes of Health, Bethesda, Maryland; the Catherine and Patrick Donaghue Medical Research Foundation, West Hartford, Connecticut; the American Heart Association, Dallas, Texas; and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. Dr. White presently serves as a safety consultant to Gilead Sciences, Inc., Foster City, California; Myriad Genetics, Inc., Salt Lake City, Utah; NicOx S.A., Sophia-Antipolis, France; Takeda Research and Development Group, Deerfield, Illinois; and Teva Neuroscience, Inc., Kansas City, Missouri. Dr. Schnitzer reports receiving research support from the National Institutes of Health; Pfizer Laboratories, Inc., New York, New York; Wyeth Laboratories, Madison, New Jersey; Nordic Bioscience, Herlev, Denmark; Novartis Pharmaceuticals Corporation; Genzyme Corporation, Cambridge, Massachusetts; and Pozen, Inc., Chapel Hill, North Carolina. Dr. Schnitzer presently serves as a consultant to Logical Therapeutics, Inc., Waltham, Massachusetts; NicOx, Inc., Warren, New Jersey; Merck & Company, Inc., Whitehouse Station, New Jersey; SantoSolve AS, Oslo, Norway; Solstice Neurosciences, South San Francisco, California; and Horizon Therapeutics, Northbrook, Illinois. Dr. Schnitzer is a noninvested shareholder of NicOx S.A. Mrs. Fleming is an employee of NicOx, Inc. Drs. Duquesroix and Beekman are employees of NicOx, S.A.

2009 ◽  
Vol 104 (6) ◽  
pp. 840-845 ◽  
Author(s):  
William B. White ◽  
Thomas J. Schnitzer ◽  
Rosanna Fleming ◽  
Brigitte Duquesroix ◽  
Maarten Beekman
Keyword(s):  
New York ◽  
New Jersey ◽  
San Francisco ◽  
Kansas City ◽  
Conflicts Of Interest ◽  
Salt Lake ◽  
Heart Association ◽  
Systemic Blood Pressure ◽  
National Institutes Of Health ◽  
Research Support

scholarly journals Working towards full eradication of lipid-driven cardiovascular risk?

2021 ◽  
Author(s):  
N. S. Nurmohamed ◽  
E. S. G. Stroes
Keyword(s):  
Clinical Investigation ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Lipid Lowering ◽  
Current Standard ◽  
Cvd Risk ◽  
Cholesterol Levels ◽  
Post Hoc ◽  
High Triglyceride

AbstractLipid-driven cardiovascular disease (CVD) risk is caused by atherogenic apolipoprotein B (apoB) particles containing low-density lipoprotein cholesterol (LDL-C), triglycerides and lipoprotein(a) [Lp(a)] and resembles a large and modifiable proportion of the total CVD risk. While a surplus of novel lipid-lowering therapies has been developed in recent years, management of lipid-driven CVD risk in the Netherlands remains suboptimal. To lower LDL‑C levels, statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibiting antibodies are the current standard of therapy. With the approval of bempedoic acid and the silencing RNA inclisiran, therapeutic options are expanding continuously. Although the use of triglyceride-lowering therapies remains a matter of debate, post hoc analyses consistently show a benefit in subsets of patients with high triglyceride or low high-density lipoprotein cholesterol levels. Pemafibrate and novel apoC-III could be efficacious options when approved for clinical use. Lp(a)-lowering therapies such as pelacarsen are under clinical investigation, offering a potent Lp(a)-lowering effect. If proven effective in reducing cardiovascular endpoints, Lp(a) lowering holds promise to be the third axis of effective lipid-lowering therapies. Using these three components of lipid-lowering treatment, the contribution of apoB-containing lipid particles to the CVD risk may be fully eradicated in the next decade.

Balancing Myocardial Ischemic and Bleeding Risks in Patients With Non-ST-Segment Elevation Myocardial Infarction††Conflicts of interest: Dr. Cohen has received grant and research support from Sanofi-Aventis, Paris, France; Merck & Company, Whitehouse Station, New Jersey; Datascope Corporation, Montvale, New Jersey; Bayer AG, Leverkeusen, Germany; AstraZeneca, Wilmington, Delaware; COR Therapeutics, Inc., San Francisco, California; Pfizer, Inc., New York, New York; and Guidant Corporation, Indianapolis, Indiana. He serves as a consultant for Datascope, Sanofi-Aventis, and AstraZeneca and is part of the speakers' bureaus of Merck & Company; Sanofi-Aventis; Schering-Plough Corporation, Kenilworth, New Jersey; and Bristol-Myers Squibb Company, New York, New York. He is not a major stock shareholder in any company. Dr. Diez serves as a consultant for Sanofi-Aventis. He is part of the speakers' bureaus of The Medicines Company, Parsippany, New Jersey; Sanofi-Aventis; and Schering-Plough Corporation. He is not a major stock shareholder in any company.

2009 ◽  
Vol 103 (10) ◽  
pp. 1396-1402 ◽  
Author(s):  
José G. Díez ◽  
Marc Cohen
Keyword(s):  
Myocardial Infarction ◽  
New York ◽  
New Jersey ◽  
San Francisco ◽  
Conflicts Of Interest ◽  
Research Support ◽  
St Segment Elevation ◽  
Segment Elevation Myocardial Infarction ◽  
St Segment

scholarly journals Genetic variation of RNF145 gene and blood lipid levels in Xinjiang population, China

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jing Ming ◽  
Xian Wei ◽  
Min Han ◽  
Dilare Adi ◽  
Jialin Abuzhalihan ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Ring Finger ◽  
Density Lipoprotein ◽  
Blood Lipid ◽  
Lipid Profiles ◽  
Cholesterol Levels ◽  
General Linear Model Analysis ◽  
Confounding Variables ◽  
Before And After ◽  
Detection Response

AbstractDyslipidemia is one of the main risk factors for coronary heart disease (CHD). The E3 ubiquitin ligase which is encoded by the ring finger protein 145 (RNF145) gene is very important in the mediation of cholesterol synthesis and effectively treats hypercholesterolemia. Thus, the purpose of the present research is to investigate the connection between the polymorphism of the RNF145 gene and cholesterol levels in the populations in Xinjiang, China. A total of 1396 participants (Male: 628, Female: 768) were included in this study for genetic analysis of RNF145 gene, and we used the modified multiple connection detection response (iMLDR) technology to label two SNPs (rs17056583, rs12188266) of RNF145 genotyping. The relationship between the genotypes and the lipid profiles was analyzed with general linear model analysis after adjusting confounding variables. Through the analysis of the two SNPs in RNF145 gene, we discovered that both rs17056583 and rs12188266 were related to total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) concentrations (All P < 0.001). In addition, the association of rs17056583 and rs12188266 with lipid profiles concentrations is still statistically significant after multivariate adjustment of sex, age, smoking, obesity, drinking, diabetes, hypertension and lipid profiles. Meanwhile, we also found that rs17056583 was associated with high triglycerides concentrations before and after adjustment (All P < 0.001). Our study shows that both rs17056583 and rs12188266 SNPs of RNP145 gene are related to TC and LDL-C concentrations in Xinjiang population.

scholarly journals The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia

Genes ◽  
2021 ◽  
Vol 12 (1) ◽  
pp. 66
Author(s):  
Alexey Meshkov ◽  
Alexandra Ershova ◽  
Anna Kiseleva ◽  
Evgenia Zotova ◽  
Evgeniia Sotnikova ◽  
...  
Keyword(s):  
Familial Hypercholesterolemia ◽  
Low Density Lipoprotein ◽  
Significant Proportion ◽  
Density Lipoprotein ◽  
Genetic Diagnostics ◽  
Atherosclerotic Cardiovascular Disease ◽  
Gene Variants ◽  
Systematic Analysis ◽  
Pcsk9 Gene ◽  
Cholesterol Levels

Familial hypercholesterolemia (FH) is a common autosomal codominant disorder, characterized by elevated low-density lipoprotein cholesterol levels causing premature atherosclerotic cardiovascular disease. About 2900 variants of LDLR, APOB, and PCSK9 genes potentially associated with FH have been described earlier. Nevertheless, the genetics of FH in a Russian population is poorly understood. The aim of this study is to present data on the spectrum of LDLR, APOB, and PCSK9 gene variants in a cohort of 595 index Russian patients with FH, as well as an additional systematic analysis of the literature for the period of 1995–2020 on LDLR, APOB and PCSK9 gene variants described in Russian patients with FH. We used targeted and whole genome sequencing to search for variants. Accordingly, when combining our novel data and the data of a systematic literature review, we described 224 variants: 187 variants in LDLR, 14 variants in APOB, and 23 variants in PCSK9. A significant proportion of variants, 81 of 224 (36.1%), were not described earlier in FH patients in other populations and may be specific for Russia. Thus, this study significantly supplements knowledge about the spectrum of variants causing FH in Russia and may contribute to a wider implementation of genetic diagnostics in FH patients in Russia.

Sign in / Sign up

Export Citation Format

Share Document